Osteocytes are the most abundant cells in bone, making up roughly ninety percent of all bone cells, and they orchestrate the constant remodeling dialogue between bone formation and bone resorption. When glucocorticoid excess strikes, trabecular bone—the spongy lattice inside vertebrae and the ends of long bones—suffers the most visible early damage. But clinicians have long observed that cortical bone, the compact shell that provides most of the skeleton’s strength, also deteriorates under prolonged steroid exposure, and that this cortical thinning correlates strongly with nonvertebral fractures. The new research provides a mechanistic account of how the cells inside cortical bone are driven to self-destruction and how their demise translates directly into mineral loss from the surrounding matrix.

The investigative team used a well-established mouse model of glucocorticoid-induced osteoporosis, in which animals receive chronic prednisolone or methylprednisolone treatment sufficient to reproduce the human pattern of rapid bone loss. Using histomorphometry, micro-computed tomography, and dynamic bone labeling, they documented substantial cortical porosity, cortical thinning, and loss of mechanical integrity. Strikingly, the loss was accompanied by a marked depletion of osteocytes within the cortical compartment and by empty lacunae—minute cavities that once housed living cells—scattered throughout the cortex. This pattern suggested that osteocyte death itself, rather than merely elevated resorption by the classic bone-dissolving osteoclasts, might be a primary event in the pathology.

To define the mode of osteocyte death, the researchers examined the molecular machinery of necroptosis, a form of regulated necrosis distinguished from apoptosis by its explosive, membrane-rupturing character and its capacity to release intracellular contents that inflame surrounding tissue. Necroptosis is executed by a signaling complex in which receptor-interacting protein kinase 1 and receptor-interacting protein kinase 3 activate the executioner protein mixed lineage kinase domain-like pseudokinase, or MLKL, which oligomerizes and punches holes in the cell membrane. In the steroid-treated mice, the team found robust activation of this pathway specifically in cortical osteocytes: phosphorylated RIPK3 and phosphorylated MLKL accumulated within lacunar cells, while markers of apoptosis were comparatively modest. Genetic or pharmacological interference with the pathway therefore became the decisive test of causality.

When the researchers crossed their glucocorticoid-treated mice with animals lacking functional MLKL, or when they treated mice with a selective RIPK1 kinase inhibitor, the picture changed dramatically. Cortical bone loss was substantially attenuated: cortical thickness was preserved, porosity declined, and biomechanical testing showed that bones retained significantly more of their strength compared with steroid-treated controls carrying intact necroptosis machinery. Osteocyte lacunae remained populated, and the hallmarks of inflammatory cell death faded. Inhibiting apoptosis, by contrast, produced only modest skeletal protection, reinforcing the conclusion that necroptosis is the dominant death program through which glucocorticoids destroy the osteocyte network in cortical bone.

The most provocative element of the study is the mechanism the authors propose for how dying osteocytes cause resorption of the mineral that surrounds them. Under normal physiological conditions, osteocytes can participate in a process called osteocytic osteolysis, in which stressed or starved osteocytes demineralize and degrade their own perilacunar matrix, releasing calcium and remolding their immediate microenvironment. The study demonstrates that necroptotic death converts this finely regulated process into a destructive free-for-all. As necroptotic osteocytes rupture, they release damage-associated molecular patterns and lysosomal enzymes that acidify the perilacunar space and dissolve the adjacent mineralized collagen matrix. In essence, each dying cell excavates the bone around it, generating the microscopic porosity that, when multiplied across millions of lacunae, hollows out the cortex from within.

Supporting this mechanism, the researchers tracked perilacunar remodeling with dynamic imaging and found that steroid exposure dramatically expanded the demineralized halos around individual lacunae, a signature of aggressive osteocytic osteolysis. They also showed that products released from necroptotic osteocytes could recruit and activate osteoclast precursors, coupling the internal excavation to conventional resorption on bone surfaces. This dual mechanism—autolytic matrix degradation by the dying cells themselves followed by secondary osteoclast activation—offers a coherent explanation for the peculiar severity and speed of glucocorticoid-induced cortical loss, which has never been fully accounted for by osteoclast activity alone.

The clinical implications are considerable. Current management of glucocorticoid-induced osteoporosis relies on calcium and vitamin D supplementation and antiresorptive agents such as bisphosphonates, which dampen osteoclast function but do nothing to protect osteocytes from dying. If necroptosis inhibition shields osteocytes from steroid toxicity in humans as it does in mice, a fundamentally new class of preventive therapy becomes conceivable: drugs that preserve the cellular network inside bone, maintaining the mechanosensory and regulatory functions that keep remodeling balanced, while simultaneously stemming the perilacunar erosion that undermines cortical strength. Inhibitors targeting the RIPK1–RIPK3–MLKL axis are already in clinical development for inflammatory and neurodegenerative diseases, which could accelerate translation into skeletal medicine.

The authors are careful to frame their conclusions within the limits of the model system. Necroptosis is a context-dependent process, and its contribution to bone loss may vary with dose, duration of steroid exposure, age, and species. Human bone biopsies from patients on long-term glucocorticoid therapy will be needed to confirm that the same molecular signature of phosphorylated MLKL and perilacunar demineralization appears in cortical osteocytes in vivo. Nonetheless, the convergence of genetic, pharmacological, and structural evidence in this study provides an unusually complete causal chain, linking a specific cell death program to a specific mode of matrix destruction and to a measurable functional outcome in the skeleton.

Beyond the immediate therapeutic horizon, the work reframes how scientists think about the skeleton’s response to stress. Osteocytes, once viewed as inert placeholders, are now firmly established as the command centers of bone, and their death by necroptosis represents a catastrophic failure of that command infrastructure. The finding that the same cells whose death is triggered by steroid excess then participate in dismantling their own mineralized surroundings blurs the boundary between cell death and bone resorption, suggesting that in disease states the two processes are woven together. For the millions of patients worldwide who depend on glucocorticoids, the study offers a concrete molecular target for keeping their skeletons intact—and a reminder that some of the most important cells in bone are the ones buried deepest inside it.

Subject of Research: Necroptosis of osteocytes as a mechanism of cortical bone resorption in glucocorticoid-induced osteoporosis

Article Title: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis

Article References: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis. (n.d.). https://doi.org/10.1038/s41420-026-03329-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03329-y

Keywords: osteocytes, necroptosis, glucocorticoid-induced osteoporosis, cortical bone, osteocytic osteolysis, MLKL, RIPK3, bone resorption, osteoclasts, perilacunar remodeling, Cell Death Discovery, bone fractures